Attached files

file filename
EX-99.1 - EXHIBIT 99.1 - CHIMERIX INCv349263_ex99-1.htm

 

 

 

UNITED STATES

 

SECURITIES AND EXCHANGE COMMISSION

 

Washington, D.C. 20549

 

FORM 8-K

 

 

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

 

 

July 2, 2013

Date of Report (Date of earliest event reported)

 

 

Chimerix, Inc.

(Exact name of registrant as specified in its charter)
     

Delaware

001-35867

33-0903395

(State or other jurisdiction (Commission File Number) (IRS Employer Identification No.)
of incorporation)    
   
   

2505 Meridian Parkway, Suite 340

Durham, NC


27713

(Address of principal executive offices) (Zip Code)
 
Registrant’s telephone number, including area code: (919) 806-1074
 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions:

 

¨Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)


¨Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 
 

 

Item 7.01Regulation FD Disclosure.

 

On July 2, 2013, we announced that M. Michelle Berrey, MD, MPH, Chimerix’s Chief Medical Officer, will provide an update on the progress of Chimerix’s CMX001 development program at the 8th Annual JMP Securities Healthcare Conference. Dr. Berrey is scheduled to present at 11:30 am ET on Wednesday, July 10, 2013, in New York City, in the press release attached hereto as Exhibit 99.1 and incorporated herein by reference.

 

 

Item 9.01Financial Statements and Exhibits.

 

(d)Exhibits

 

Exhibit No.   Description
99.1   Press Release of Chimerix, Inc. dated July 2, 2013.

 

 
 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

    Chimerix, Inc.
     
Dated: July 2, 2013    
    By: /s/ Timothy W. Trost    
      Timothy W. Trost
      Senior Vice President, Chief Financial Officer and Corporate Secretary

  

 
 

 

INDEX TO EXHIBITS

 

 

Exhibit No.   Description
99.1   Press Release of Chimerix, Inc. dated July 2, 2013.